Literature DB >> 31103618

Role of the endocannabinoid and endovanilloid systems in an animal model of schizophrenia-related emotional processing/cognitive deficit.

Valéria Almeida1, Raquel Levin1, Fernanda Fiel Peres2, Mayra Akimi Suiama1, Ana Maria Vendramini1, Camila Maurício Santos1, Neide Derci Silva1, Antonio Waldo Zuardi3, Jaime Eduardo Cecílio Hallak3, José Alexandre Crippa3, Vanessa Costhek Abílio4.   

Abstract

Studies suggest that the endocannabinoid and endovanilloid systems are implicated in the pathophysiology of schizophrenia. The Spontaneously Hypertensive Rats (SHR) strain displays impaired contextual fear conditioning (CFC) attenuated by antipsychotic drugs and worsened by pro-psychotic manipulations. Therefore, SHR strain is used to study emotional processing/associative learning impairments associated with schizophrenia and effects of potential antipsychotic drugs. Here, we evaluated the expression of CB1 and TRPV1 receptors in some brain regions related to the pathophysiology of schizophrenia. We also assessed the effects of drugs that act on the endocannabinoid/endovanilloid systems on the CFC task in SHRs and control animals (Wistar rats - WRs). The following drugs were used: AM404 (anandamide uptake/metabolism inhibitor), WIN55-212,2 (non-selective CB1 agonist), capsaicin (TRPV1 agonist), and capsazepine (TRPV1 antagonist). SHRs displayed increased CB1 expression in prelimbic cortex and cingulate cortex area 1 and in CA3 region of the dorsal hippocampus. Conversely, SHRs exhibited decreases in TRPV1 expression in prelimbic and CA1 region of dorsal hippocampus and increases in the basolateral amygdala. AM404, WIN 55,212-2 and capsaicin attenuated SHRs CFC deficit, although WIN 55,212-2 worsened SHRs CFC deficit in higher doses. WRs and SHRs CFC were modulated by distinct doses, suggesting that these strains display different responsiveness to cannabinoid and vanilloid drugs. Treatment with capsazepine did not modify CFC in either strains. The effects of AM404 on SHRs CFC deficit was not blocked by pretreatment with rimonabant (CB1 antagonist) or capsazepine. These results reinforce the involvement of the endocannabinoid/endovanilloid systems in the SHRs CFC deficit and point to these systems as targets to treat the emotional processing/cognitive symptoms of schizophrenia.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Cannabinoid drugs; Contextual fear conditioning; SHR; Schizophrenia; Vanilloid drugs

Mesh:

Substances:

Year:  2019        PMID: 31103618     DOI: 10.1016/j.neuropharm.2019.05.015

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  5 in total

1.  Distribution and Assembly of TRP Ion Channels.

Authors:  Wei Cheng; Jie Zheng
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  On the Biomedical Properties of Endocannabinoid Degradation and Reuptake Inhibitors: Pre-clinical and Clinical Evidence.

Authors:  Karen Jaqueline Paredes-Ruiz; Karla Chavira-Ramos; Mario Orozco-Morales; Cimen Karasu; Alexey A Tinkov; Michael Aschner; Abel Santamaría; Ana Laura Colín-González
Journal:  Neurotox Res       Date:  2021-11-06       Impact factor: 3.911

3.  Cannabinoids modulate proliferation, differentiation, and migration signaling pathways in oligodendrocytes.

Authors:  Valéria de Almeida; Gabriela Seabra; Guilherme Reis-de-Oliveira; Giuliana S Zuccoli; Priscila Rumin; Mariana Fioramonte; Bradley J Smith; Antonio W Zuardi; Jaime E C Hallak; Alline C Campos; José A Crippa; Daniel Martins-de-Souza
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-05-27       Impact factor: 5.760

Review 4.  Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders.

Authors:  Daniela Navarro; Ani Gasparyan; Francisco Navarrete; Abraham B Torregrosa; Gabriel Rubio; Marta Marín-Mayor; Gabriela B Acosta; Maria Salud Garcia-Gutiérrez; Jorge Manzanares
Journal:  Int J Mol Sci       Date:  2022-04-26       Impact factor: 6.208

5.  The endocannabinoidome as a substrate for noneuphoric phytocannabinoid action and gut microbiome dysfunction in neuropsychiatric disorders
.

Authors:  Vincenzo Di Marzo
Journal:  Dialogues Clin Neurosci       Date:  2020-09       Impact factor: 5.986

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.